Abstract With the advent of effective combination antiretroviral therapy, HIV infection has been transformed from a fatal disease to a chronic condition. There is renewed clinical interest in long-term morbidities, including malignancies that occur disproportionately within this population. Non-AIDSdefining cancers (NADCs) are a significant source of morbidity and mortality in the aging HIV-infected population. There are data to suggest that incidence rates are elevated among HIV-infected individuals for many cancer sites, particularly those with a confirmed or suspected infectious etiology. The complex interplay between behavioral risk factors, coexistence of viral infections, immunodeficiency and antiretroviral therapy makes it difficult to analyze why certain cancers develop more frequently in HIV-infected individuals. The challenge to clinicians caring for HIV-infected patients is to develop and implement effective means to screen, treat, and prevent NADCs in the future. This review presents data on whether NADCs are increased in the HIV-Infected population, as well as ongoing research on epidemiology, prevention and pathogenesis of this evolving aspect of the HIV epidemic.
Introduction
Infection with HIV increases the risk of certain types of cancer. The risk of Kaposi's sarcoma and non-Hodgkin's lymphoma (NHL) is significantly greater among HIVinfected persons. Therefore these types of cancer are included in the Centers for Disease Control and Prevention's definition of AIDS-defining conditions [1] . Invasive cervical cancer was added to this list of conditions in 1993 not simply for increased prevalence but also because HIV infection may adversely affect its clinical course and treatment. More recently, it has been suggested that persons with HIV infection develop non-AIDS-related types of cancer more frequently than the general population [2] [3] [4] [5] [6] . This may be explained by multiple mechanisms, which include improvement in life expectancy with antiretroviral therapy [7] [8] [9] , premature aging [10, 11] , loss of control of oncogenic infections due to HIV-related immune suppression [12, 13] and a high prevalence of exposure to other carcinogens such as tobacco and alcohol [2, 14] .
Since an exhaustive review of HIV and its impact on risks for all malignancies cannot be easily done, infectionrelated non-AIDS-defining cancers (NADCs), lung cancer and Hodgkin's lymphoma (HL) have been selected for their strength of association with HIV. In addition to age, traditional risk factors (such as tobacco use), immunodeficiency and chronic viral coinfections all contribute to the increase in incident cancer rates in the HIV-infected population, and influence prevention and screening of these malignancies.
Epidemiology of Non-AIDS-Defining Cancers
The use of highly active antiretroviral therapy (HAART) has dramatically improved survival among HIV-infected persons and has decreased the incidence of AIDS. Shortly after the advent of HAART, the mortality rate for those infected with HIV declined by at least 40 % [7] [8] [9] . The HIV-infected population in the US expanded fourfold from 1991 to 2005, largely because of an increase in the number of people with HIV aged 40 years and older [15••] . As a result, by the end of 2009, approximately 1.1 million persons in the US were living with HIV/AIDS [16] . From 2008 through 2010, the prevalence of HIV/AIDS increased by 26 % among persons aged 65 years and older [16] . By 2015, more than half of people living with HIV/AIDS in the US will be more than 50 years of age [11] . Notably, a 20-year-old HIV-infected adult on ART in the US or Canada is expected to live into their early 70's, a life expectancy approaching that of the general population [17] . Therefore, attention must be paid to health maintenance measures, including age-appropriate cancer screening, for the growing HIV-infected population; and understanding underlying epidemiology for those malignancies is paramount for establishing screening guidelines.
Despite its unquestioned success in prolonging survival among those infected with HIV, HAART does not fully restore health. For reasons that remain poorly defined, HIV-infected persons on long-term treatment have an expected life span that is still shorter than their HIV-uninfected peers [18, 19] . This shortened life span is largely due to an increased risk of a number of non-AIDS complications, including cardiovascular disease, liver disease, kidney disease, bone disease, and neurocognitive decline [20] . Many of these complications are similar to those observed among the elderly. These observations have led to growing concern that HIV-infected persons suffer from accelerated or premature aging.
With a few exceptions, cancer is primarily a disease of aging. Understandably, the burden of cancer, particularly NADCs, is likely to increase as HIV-infected persons live longer. From 1991 -1995 to 2001 -2005, the estimated number of NADCs increased by approximately threefold, whereas the number of AIDS-defining cancers decreased by more than threefold [15••] . Yanik et al. evaluated the incidence and timing of cancer diagnoses among patients initiating ART between 1996 and 2011 in a collaboration of eight US clinical HIV cohorts, and found that incidence rates for all NADCs combined increased from 1 to 10 years after ART initiation (average 7 % increase per year; 95 % confidence interval 2 -13 %) [21] . Data from the Veterans Affairs Healthcare System shows that the incidence of NADCs is higher among HIVinfected than HIV-uninfected patients, even after adjusting for age, race, and gender [22] . In addition, median CD4 counts were lower in those with NADCs, anal cancer, and HL among HIV-infected patients in this cohort. The French Hospital
Database also shows that current CD4 count is the most significant predictive factor for all malignancies except anal cancer [23] . These findings highlight the importance of ongoing aggressive cancer screening and prevention efforts throughout the course of HIV care.
For cancer, premature aging could manifest not only as an overall elevated cancer risk but also as a downward shift in the distribution of ages at cancer diagnosis. Studies of lung [24] [25] [26] , liver [27, 28] , anal [29] , and colorectal cancer [30] have shown that ages at diagnosis are 10 to 20 years younger among persons with HIV compared with the general population. However, HIV tends to be acquired at a young age and persons with HIV have a shorter life expectancy than those without HIV. As a result, the proportion of persons with HIV who are older is far smaller than in the general population. For example, in the US in 2010, only 4 % of HIV-infected persons were aged 65 years or older [16] , compared with 13 % of the general population [31] . Because overall cancer incidence is ten times higher in persons aged 65 years or older than in persons younger than 65 years [32] , the truncated age distribution among persons with HIV precludes observation of most instances of cancer that would occur at older ages, which could explain the dramatic age differences at the time of cancer diagnosis shown in previous studies.
Notably, the HIV Cancer Match Study showed that although modest age differences remain for lung cancer, anal cancer and HL, the median ages at diagnosis in the AIDS and general populations did not differ for most types of cancer (e.g. colon, prostate, and breast cancer) after adjustment for differences in the age structure of populations at risk [33] . These findings do not support premature aging in HIVinfected persons. As the HIV/AIDS population continues to age, more cases of NADCs will be expected to occur at older ages, which would attenuate or eliminate the apparent age differences at cancer diagnosis.
Infection-Related Cancers
Substantially greater risk of cancers with a known infectious cause in HIV-infected persons compared with HIV-uninfected persons has been demonstrated in multiple studies. Infectionrelated cancers (including AIDS-defining cancers) comprised almost 70 % of all cancers in HIV-infected persons enrolled in an integrated healthcare system in California compared with only 12 % in HIV-uninfected persons of similar age and sex [12] . In this cohort, HIV-infected persons had a more than ninefold increased risk of infection-related NADC than HIVuninfected persons, which was largely influenced by differences in the risk of anal squamous cell cancer.
Viral coinfections including human papillomavirus (HPV) [34] , and hepatitis B virus (HBV) and hepatitis C virus (HCV) [35] are common in HIV-infected persons. The suppressed immune system of HIV-infected persons reduces the ability to control oncogenic viral process, which could explain the greater risk of infection-related cancer in the HIV-infected population. This hypothesis is supported by a large metaanalysis by Grulich et al. [13] who compared cancer incidences in population-based cohort studies of persons with HIV infection and organ transplant recipients. Many cancers that occurred with higher frequencies in both populations compared with the general population had a known or suspected infectious cause. Since these two populations have vastly different lifestyle and traditional risk factor profiles, immune deficiency, rather than other risk factors for cancer, is responsible for the increased risk. Infection-related cancers, including anal cancer, oropharyngeal cancer and hepatocellular carcinoma (HCC), will likely become increasingly significant complications of long-term HIV infection.
Anal Cancer
Although anal cancer is uncommon in the general population [32] , its incidence has been rising for several decades [36] . In the US, the rates of anal cancer among men who have sex with men (MSM) and immunosuppressed men now exceed the rates of cervical cancer among women [37] . As such, anal cancers have become an important cause of morbidity among HIV-infected persons [5] . In the NA-ACCORD study, HIVinfected MSM had the greatest risk of anal cancer with incidence rates greater than 80 times those among HIV-uninfected individuals. Both HIV-infected men and women had substantially higher rates than HIV-uninfected men and women, and HIV-infected men and women had similar rates [38] .
The impact of ART on the incidence of anal cancer, however, is somewhat conflicting. Using longitudinal data from the US Military Natural History Study (1985 -2005) , the incidence rates of anal cancer have progressively increased during the HIV epidemic. Crum-Cianflone et al. noted that persons with HIV infection for more than 15 years had a 12-fold higher rate of anal cancer than those with infection for less than 5 years [29] . This suggests that the improved survival among HIV-infected individuals in the HAART era results in longer exposure to HPV infection, which may result in increased risk of HPV-associated cancers. However, in a different cohort, the incidence of anal cancer declined during 2004 -2007 as compared to 1996 -1999 [12] . In another study, the rates of anal cancer among HIV-infected individuals increased after the early ART era and then plateaued in more recent years [38] . These conflicting results perhaps reflect the competing forces of improvement in immune function with HAART leading to better control of coinfections, and underlying immunosuppression [39•] .
The relationship between CD4 count and anal cancer is also unclear. Using multivariate models, it has been demonstrated that a longer exposure to CD4 cell counts <200 cells/ mm 3 was associated with incident anal cancer. However, those with higher CD4 counts also had increasing anal cancer incidence rates between 1996 -1999 and 2000 -2003 [38] . As life expectancy among HIV-infected persons is increasing and HAART does not appear to be protective against anal cancer, studies on preventive strategies are needed.
Head and Neck Cancers
While the majority of head and neck squamous cell cancers (HNSCC) worldwide are attributable to tobacco and alcohol exposure, oral HPV infection has recently been noted to be an important cause of head and neck cancer [41] . HPV16 accounts for the overwhelming majority (90 -95 %) of HPVpositive oropharyngeal cancers, and HPV18, 33, 35, 45, and 59 account for the remainder [42] . Individuals with HIV/ AIDS are consistently reported to have a twofold to fourfold greater risk of head and neck cancer [43, 44] . In a recent metaanalysis, the risk of oral cavity and pharynx cancer was twofold higher among persons with HIV/AIDS [13] . When risk is stratified by anatomic site of the tumor, the risk of HPVrelated HNSCC (i.e. oropharyngeal or tonsillar) is consistently elevated from twofold to sixfold [45] .
In the HIV Cancer Match study, the risk of oral cavity/ pharynx cancer was elevated among HIV-infected individuals with mild-moderate immunosuppression (median CD4 count about 500 cells/mm 3 ) prior to AIDS diagnosis (standardized incidence ratio 1.7, 95 % CI 1.1 -2.5]. The incidence rates for oropharyngeal cancer also increased with severity of immunosuppression, as demonstrated by the fact that the risk of oropharyngeal cancer was increased in HIV-infected individuals after compared with before the diagnosis of AIDS (relative risk 3.6, 95 % CI 1.6 -8.2) [3] . However, HAART does not appear to reconstitute HPV-specific immunity, as some reduction in risk of oropharyngeal cancer in the post-HAART era (standardized incidence ratio 0.6, 95 % CI 0.3 -1.4) has been reported [3] , but not consistently [14, 44] .
Hepatocellular Carcinoma
Persons infected with HIV, especially injecting drug users (IDU), have a greatly increased incidence of HBV and HCV infection compared with the general population; therefore, they are at a greater risk of HCC [13, 46] . Early studies on the natural history of HIV and hepatitis coinfection have shown that HIV-related immunosuppression worsens the risk of cirrhosis and liver-related death [47] . However, in the era of HAART, coinfected patients do not necessarily have a higher incidence of HCC than monoinfected patients [48] .
HAART, along with better HCV treatments and improved medical management of advanced liver disease, may be associated with a decreased risk of hepatic decompensation and increased survival of coinfected patients with cirrhosis. As a result, the probability of developing HCC has become elevated [49] [50] [51] . HIV/HCV-coinfected patients in older studies typically received suboptimal ART, and uncontrolled HIV infection might have shortened the survival of coinfected patients with end-stage liver disease to such an extent that possibly HCC did not have a chance to emerge. In one recent cohort of treated HIV-infected patients with primarily HCVinduced cirrhosis, the incidence of HCC was as high as 6.7 per 1,000 patient-years [52] .
Both HBV and HCV cause HCC, but the difference in their predominant route of transmission leads to the fact that HIVinfected MSM who develop HCC are more likely to have HBV, whereas HIV-infected IDU with HCC would be more likely to have HCV [27, 28] . HIV worsens the clinical outcome of HBV infection by hastening progression to cirrhosis [53] and liver-related death [54] , particularly at low CD4 counts [55] . A nested case control study in the Swiss HIV Cohort Study showed that lower CD4 cell counts increase the risk for HCC among persons infected with HIV. The effects of CD4 cell count are predominantly noted in the risk categories of MSM, heterosexual and other, rather than IDU [56] . It has been speculated that the association of HBV with HCC is stronger than that of HCV with HCC. However, the number of individuals with HCC in this study was small and limited its statistical power. The significance of the dichotomy between HBV-positive HCC arising in MSM and HCV-positive HCC in IDU should be validated in larger cohorts.
Lung Cancer
Lung cancer is the most common NADC and the leading cause of cancer-related mortality among HIV-infected individuals [57] . Increased rates of lung cancer in HIV-infected patients, compared with uninfected patients, have been demonstrated in multiple prior studies [58-60, 61•, 62, 63] , but they were variously affected by important limitations. For example, Chaturvedi et al. found that the risk of lung cancer was elevated among people with AIDS in the 4 -27 months after AIDS diagnosis, and the risk was especially high among those aged under 30 years of age. However, actual smoking data were not available and the observed incidence was compared with general population rates and rates from a lung cancer prediction model for smokers [58] . A retrospective cohort study at a HIV specialty clinic in Baltimore conducted by Engels et al. also found increased lung cancer risk even after adjustment for smoking [60] . Unfortunately, they did not have an HIV-uninfected cohort for comparison and they used SEER data from Detroit, an urban center similar to Baltimore [60] . Engels et al. found that HIV-infected individuals had twice the risk of lung cancer in the AIDS Link to the Intravenous Experience (ALIVE) cohort [60] . However, this study enrolled between 1988 and 2003, when mortality due to AIDS events still dominated clinical outcomes [60] . Finally, Levine et al. conducted a prospective study of lung cancer incidence using data from the Women's Interagency HIV Study and demonstrated that HIV infection was strongly associated with smoking behaviors that increase lung cancer risk [62] . Only 14 patients with lung cancer were identified, however, which significantly limited their statistical power [62] . The major confounding factor was that there is a higher prevalence of smoking in HIV-infected patients compared with most of the general US population [63] .
HIV was established as an independent risk factor for lung cancer using data from the Veterans Aging Cohort Study and Veterans Affairs Central Cancer Registry [64] . The incident rate ratio (IRR) of lung cancer associated with HIV infection remained significant (IRR 1.7, 95 % CI 1.5 -1.9) after adjusting for age, sex, race/ethnicity, smoking prevalence, previous bacterial pneumonia, and chronic obstructive pulmonary disease. Lung cancer stage at presentation did not differ between HIVinfected and uninfected patients, indicating that surveillance bias was an unlikely explanation for this finding [64] .
The relationship between CD4 cell count, degree of immunosuppression, and subsequent predisposition for lung cancer remains unclear. A large, multicenter cohort study of 20,775 HIV-infected persons showed a trend toward increased incidence of lung cancer in those with a CD4 cell count at or below 200 cells/mm 3 (relative risk 2.2, 95 % CI 1.3 -3.6) [40•]. However, this study also showed that the incidence rates for lung cancer were similar between HIV-infected and HIVnegative persons once adjusted for factors related to demography and infection. In contrast, a study by Prosperi et al. showed increased incidence of NADCs (including lung cancer) in persons with CD4 cell counts of at least 500 cells/mm 3 [65] . Because the absolute risk of developing a malignancy with a CD4 cell count >350 cells/mm 3 does not seem to be zero, these findings further support the need to continue to study the potential effect of starting HAART earlier than is recommended by the present guidelines.
Hodgkin's Lymphoma
The incidence of HL is approximately tenfold higher in people with HIV infection [13] . The HL in persons with HIV/AIDS is mostly mixed cellularity and lymphocyte-depleted subtypes, whereas the nodular-sclerosing subtype predominates in young adults without HIV/AIDS [66, 67] . It is not surprising that HIV/AIDS-related immunosuppression would affect HL risk and subtype distribution, since persons with genetic conditions associated with T-lymphocyte immune dysfunction have a higher risk of HL, and patients with HL may have underlying abnormalities of T-cell immunity [67] .
The overall relative risk for the development of HL has been found to be elevated in HIV-infected men and women regardless of route of HIV transmission starting from 60 months before AIDS to after the onset of AIDS [45] . Therefore, HL is likely to be genuinely associated with immune dysfunction. However, it is interesting that the incidence of HL has not decreased in the HAART era, and indeed two large studies in the US have shown increasing rates [2, 3, 5] . Among people with AIDS, rates of HL are highest in those with moderate rather than profound immunodeficiency, and nodular-sclerosing HL is uncommon in those with severe immunodeficiency [68] .
The relationship between immunodeficiency, HL development and HL subtypes is unclear. HAART use has improved immunity after AIDS onset, paradoxically increasing HL incidence among persons with HIV/AIDS. The cellular background surrounding Hodgkin and Reed-Sternberg cells may be altered with severe immunosuppression [69] [70] [71] [72] [73] [74] . Whether this change affects categorization as HL or whether it inhibits or delays HL development is unknown. Epstein-Barr virus (EBV) DNA is detectable in a high proportion of patients with AIDS-associated HL [75] . Patients with AIDS-associated NHL are also often EBV-positive [76] . Both HL and NHL appear to develop from B-lymphocyte transformation [77] . Therefore, EBV-associated subsets of HL may be associated with immune dysfunction through similar mechanisms underlying the association with NHL.
Conclusion
NADCs are a rising health concern among HIV-infected patients. HIV-infected patients are at increased risk of several cancers compared to the general population. There is good evidence that the risk of anal cancer, HCC, HL, and lung cancer is enhanced in the HIV-infected population. However, the higher risk of lung cancer suggests a greater impact of smoking and the need for smoking cessation, and should be evaluated further. Prevention efforts in HIV-infected persons should continue to focus on infection-related cancers, including screening for anal dysplasia and the evaluation of more routine vaccinations and antiviral treatment for infections such as HBV infection. There is currently an AIDS Malignancy Consortiumsponsored clinical trial for HPV vaccine in young HIVinfected MSM. For anal squamous cell cancer, universal guidelines for screening and detection of early lesions may also greatly benefit this population. The care of patients with HIV will become more complicated as patients grow older, as they develop additional comorbidities and their treatment becomes more complex due to the presence of HIV. Multidisciplinary teams will be needed to confront unique challenges that arise.
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